Insulin-induced electrophysiology changes in human pleura are mediated via its receptor.
BACKGROUND
Insulin directly changes the sheep pleural electrophysiology. The aim of this study was to investigate whether insulin induces similar effects in human pleura, to clarify insulin receptor's involvement, and to demonstrate if glibenclamide (hypoglycemic agent) reverses this effect.


METHODS
Human parietal pleural specimens were mounted in Ussing chambers. Solutions containing insulin or glibenclamide and insulin with anti-insulin antibody, anti-insulin receptor antibody, and glibenclamide were used. The transmesothelial resistance (R(TM)) was determined. Immunohistochemistry for the presence of Insulin Receptors (IRa, IRb) was also performed.


RESULTS
Insulin increased R(TM) within 1st min (P = .016), when added mesothelially which was inhibited by the anti-insulin and anti-insulin receptor antibodies. Glibenclamide also eliminated the insulin-induced changes. Immunohistochemistry verified the presence of IRa and IRb.


CONCLUSIONS
Insulin induces electrochemical changes in humans as in sheep via interaction with its receptor. This effect is abolished by glibenclamide.
Kouritas
V K
VK
Department of Physiology, Medical School, University of Thessaly, Mezourlo, New Buildings, Larissa, Greece. kouritas@otenet.gr
Ioannou
M
M
Foroulis
C N
CN
Desimonas
N
N
Evaggelopoulos
K
K
Gourgoulianis
K I
KI
Molyvdas
P A
PA
Hatzoglou
C
C
D005905:Glyburide / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D010994:Pleura / Q000187:drug effects* / Q000502:physiology; D017526:Receptor, IGF Type 1 / Q000502:physiology; D011972:Receptor, Insulin / Q000032:analysis / Q000502:physiology*
D007328:Insulin; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D005905:Glyburide
Br J Pharmacol. 2000 Jul;130(6):1255-62
10903963
J Pharmacol Exp Ther. 1993 May;265(2):933-7
8496833
J Gen Physiol. 1999 Oct;114(4):561-74
10498674
J Am Soc Nephrol. 2007 Jun;18(6):1652-61
17442787
Eur J Gastroenterol Hepatol. 2003 May;15(5):545-9
12702914
Exp Clin Endocrinol Diabetes. 1996;104(1):1-9
8750563
Eur Respir J. 2007 Aug;30(2):354-7
17666558
Am J Physiol. 1977 Mar;232(3):F270-7
402826
Am J Physiol. 1998 May;274(5):C1373-9
9612225
J Pharmacol Exp Ther. 2003 Feb;304(2):833-40
12538840
J Membr Biol. 1999 Mar 1;168(1):91-101
10051692
Am J Physiol. 1985 Jul;249(1 Pt 2):F1-11
3893158
Br J Pharmacol. 2005 Aug;145(8):1069-75
15912128
Br J Pharmacol. 2000 Aug;130(7):1678-84
10928974
Am J Physiol. 1984 Nov;247(5 Pt 1):C472-7
6093574
Am J Physiol. 1992 Jan;262(1 Pt 1):C207-13
1310212
Diabetes. 1993 Jul;42(7):1032-40
8513970
Biochem Biophys Res Commun. 2002 Feb 22;291(2):394-9
11846418
Biol Pharm Bull. 2001 Apr;24(4):385-9
11305600
J Appl Physiol (1985). 2001 Apr;90(4):1565-9
11247961
J Pharm Sci. 2002 Apr;91(4):1135-46
11948552
Diabet Med. 2007 Nov;24(11):1282-5
17956453
Am J Physiol. 1989 Oct;257(4 Pt 1):C612-20
2552816
Am J Physiol. 1965 Oct;209(4):819-24
5843433
Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):213-25
8878050
Am J Kidney Dis. 2004 Oct;44(4):575-90
15384008
Physiol Rev. 2004 Apr;84(2):385-410
15044678
Endocr Rev. 1999 Apr;20(2):101-35
10204114
Exp Clin Endocrinol Diabetes. 2010 May;118(5):304-9
19856254
J Vet Med A Physiol Pathol Clin Med. 2006 Feb;53(1):5-11
16411900
Am J Physiol Cell Physiol. 2004 Mar;286(3):C586-95
14592811
Pflugers Arch. 1996 Aug;432(4):685-91
8764970
Pflugers Arch. 2005 Dec;451(3):445-53
16170524
J Investig Med. 2004 Mar;52(2):104-8
15068225
Physiol Rev. 2003 Oct;83(4):1113-51
14506302